Home > Insider Trading > Filing (0000899243-20-035182)

Filing Details

Accession Number:: 0000899243-20-035182
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-12-28 16:05:13
Reporting Period:: 2020-12-23

Accepted Time:: 2020-12-28 16:05:13
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1531048	Inari Medical Inc.	NARI	()	P7

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1420106	B.v. Holding Healthcare Gilde	Newtonlaan 91 3584 Bp Utrecht P7	No	No	Yes	No
1756335	U.a. Iv Healthcare Gilde Cooperatieve	Newtonlaan 91 3584 Bp Utrecht P7	No	No	Yes	No
1757508	B.v. Management Iv Healthcare Gilde	Newtonlaan 91 3584 Bp Utrecht P7	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2020-12-23	46,365	$79.51	6,200,150	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-23	164,392	$80.45	6,035,758	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-23	42,643	$81.36	5,993,115	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-23	8,926	$82.04	5,984,189	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-23	2,234	$83.40	5,981,955	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-23	1,208	$84.27	5,980,747	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-24	5,852	$80.79	5,974,895	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-24	22,439	$81.73	5,952,456	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-24	8,830	$82.64	5,943,626	No	4	S	Indirect	See footnote
Common Stock	Disposition	2020-12-24	1,947	$83.47	5,941,679	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $78.90 to $79.895, inclusive. The Reporting Persons undertake to provide to Inari Medical, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
All securities reported are held of record by Cooperatieve Gilde Healthcare IV U.A. ("Gilde"). Gilde is managed by Gilde Healthcare IV Management B.V. ("Management"). Management is owned by Gilde Healthcare Holding B.V. ("Holding"). Each of Management and Holding may be deemed to have voting, investment and dispositive power with respect to the securities held by Gilde. Each of Management and Holding disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities, except to the extent of their respective pecuniary interests therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $79.925 to $80.92, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $80.925 to $81.88, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $81.90 to $82.88, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.91 to $83.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $84.09 to $84.91, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $80.13 to $81.12, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $81.19 to $82.16, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $82.205 to $83.19, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $83.325 to $83.62, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.